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These results demonstrate that both pain interference score
and pain intensity are significant predictors of overall survival in
men with castrate-refractory prostate cancer. Furthermore, pain
interference score and pain intensity are statistically significant
predictors of overall survival even when adjusting for established
prognostic factors. It is known that high levels of alkaline phospha-
tase, PSA, and lactate dehydrogenase; low levels of hemoglobin;
and high Gleason scores are indicators of advanced progression
and death. Thus, these findings support the hypothesis that pain
intensity and pain interference score are validated measures of
advanced disease in men with prostate cancer. We agree with
Klepstad and Kaasa in that investigating the relationship between
pain and clinical outcomes in cancer patients is a fruitful area
of research.
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Mutations of KRAS and BRAF in
Primary and Matched Metastatic
Sites of Colorectal Cancer
TO THE EDITOR: After the demonstration that KRAS or BRAF
mutations in colorectal cancer (CRC) are associated with clinical
resistance to treatment with the epidermal growth factor receptor
(EGFR)–targetedmonoclonal antibodies,1-3 the clinical confirmation
of these findings in independent retrospective reports4,5 as well as in a
phase III trial recently published in Journal ofClinicalOncologyhas led
the EuropeanMedicines Agency to license panitumumab and cetux-
imab only for patients with CRCwithoutKRASmutations.6,7 Never-
theless, among patients with wild-type KRAS CRC, the objective
response rate is limited to 17% (v 0% in unselected patients) with
panitumumabmonotherapy8 and to 59% and 61% (v 43% and 33%
in unselected patients) with cetuximab plus either irinotecan- or
oxaliplatin-based chemotherapy, respectively.9,10 These data indicate
that othermechanisms of resistance play a significant role.Moreover,
evaluation of metastatic rather than primary sites could be of clinical
relevance because occurrence of amutation in themetastasis could, at
least theoretically, explain resistance despite a wild-type primary tu-
mor. Scarce andheterogeneous reports have evaluatedwhetherKRAS
status matches in primary tumor and metastatic site(s),11-14 whereas
BRAF remains unexplored. For these reasons, we elected to evaluate
KRAS (exon2)andBRAF (exon15)byDNAsequencing inacohortof
48 CRC patients (median age, 56 years; range, 37 to 79 years; 28 men
and 20women) in primary tumor (colon, n 32; rectum, n 7; and
sigma-rectum junction, n9) andmatchedmetastases (liver, n39;
ovary, n  2; distant lymph nodes, n  1; adrenal gland, n  1;
pancreas, n1; lung,n2;omentum,n1; andpelvicmass, n1).
DNA sequencing showed a frequency of mutation in the primary
tumorormetastases of 13 (27%)of 48 and two (4%)of 48patients for
KRAS and BRAF, respectively. None of the patients carried bothmu-
tations (in primary tumor ormetastasis); the occurrence of themuta-
tions was a mutually exclusive phenomenon, as expected by
literature.15 We observed an overall concordance ofKRAS and BRAF
mutational status (ie, mutated or wild type) between primary tumor
andmetastasis in 44 (92%) of 48 patients. In patients carrying aKRAS
mutation, concordance between primary tumor and secondary de-
posits was observed in 10 (77%) of 13 patients, all but one of whom
presented with synchronous metastases (Table 1). Discordance of
KRAS mutational status was detected in three (23%) of 13 patients
with mutations, with one patient carrying KRAS mutation in the
primary tumor only and two patients carrying the mutation in the
metastatic siteonly (pancreasandadrenal gland).Notably,occurrence
of KRAS mutations with wild-type primary tumor was detected in
extrahepatic sites only. In the two patients carrying BRAF mutation,
one patient presented the samemutation in both primary tumor and
metastasis, whereas the other patient presented the mutation in the
primary tumor site only.
Controversial and heterogeneous previous reports11-14 demon-
strated overall concordance betweenKRASmutations in the primary
tumor and secondary deposits in CRC, indicating that KRAS muta-
tions are not essential for the attainment of metastatic capacity. In a
previous study, Oudejans et al11 evaluated 39 patients and found, in
three patients, a KRAS point mutation in the metastasis with a
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wild-typeprimary tumor,whereas ina singlepatient, apointmutation
was found in a primary tumor but was absent from the metastasis.
Moreover, these investigators did not find differences in frequency of
KRAS mutations between 23 patients with isolated lung metastases
and 20 patients with liver metastases (57% and 50%, respectively),
demonstrating thatKRAS oncogene activation does not have amajor
role in determining the frequency of lung metastases versus liver
metastases. Suchy et al12 demonstrated the concordance of KRAS
mutations inprimary tumors and respectivemetastases in 15patients,
and the type ofmutationwas also identical in the instance of different
metastases fromthe sameprimary tumor localized indifferentorgans,
indicatinga stabilityof thesemutationsduringmetastaticprogression.
In a series from 1998, Al-Mulla et al13 reported that only two (8%) of
26metastatic patients had amutation in their primary carcinoma but
none in liver metastases. In contrast with these data showing overall
identity of KRAS mutations between primary tumor and matched
metastatic deposits, To´rtola et al14 described discordance between
KRAS mutation in bone marrow micrometastases and primary tu-
mor. In particular, in six patients with primary tumormutations, the
patternofKRASmutationdiffered in threepatients, and inonepatient
the samemutationplus adifferent onewere found;moreover, in eight
patients, therewas amutation in theprimary tumor andnone inbone
marrowmetastases. In the present cohort, we took into consideration
KRAS andBRAFmutations because alterations of both of these cellu-
lar effectors can impair response to anti-EGFR therapy. For both
genetic alterations,weobservedoverall concordancebetweenprimary
tumor andmetastasis in the vastmajority of patients. Present findings
represent additional knowledge supporting the notion that a concor-
dance ofKRAS andBRAF status is themost common feature in CRC.
The clinical relevance of these data is that evaluation of theKRAS and
BRAFmutations can be performed in either primary tumor ormeta-
static site(s) and that absence of such mutations could be enough to
drive the selection of metastatic CRC patients who are candidates for
anti-EGFRmonoclonal antibody therapy.
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Table 1. Molecular and Clinical Characteristics of Patients With Colorectal Cancers Harboring KRAS or BRAF Mutations
Patient No.
Primary Tumor First Metastatic Site Other Metastatic Site
Tumor Site KRAS BRAF Metastasis Site KRAS BRAF Metastasis Site KRAS BRAF
1 Colon G12S NA Liver G12S NA
2 Colon G12D WT Liver G12D WT
3 Rectum G12D WT Liver G12D WT Liver G12D WT
4 Rectum G12D WT Liver G12D WT
5 Colon G13D WT Liver G13D WT
6 Sigma-rectum G12S WT Liver WT WT
7 Colon G13D WT Liver G13D WT
8 Colon WT V600E Omentum WT V600E
9 Sigma-rectum G13D WT Liver G13D WT
10 Colon G12C WT Liver G12C WT
11 Colon G12V WT Ovary G12V WT
12 Colon G13D WT Liver G13D WT
13 Colon WT V600E Pelvis WT WT
14 Colon WT WT Pancreas G12V WT
15 Rectum WT WT Adrenal gland G12V WT Kidney G12V WT
Abbreviations: NA, not assessable; WT, wild type.
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Detailed Analysis of Visitors to
Cancer-Related Web Sites
TO THE EDITOR:Web sites are a valuable source of information
for cancer patients.1 Patients are seeking information necessary for
their own treatment, as well as general cancer information. To
satisfy such needs of cancer patients, it is necessary to build Web
sites that are conducive to patients’ individual needs, as well as to
have organic linkage between a wide variety of sites. Although
achieving this end requires sufficient study of the characteristics of
cancer-related Web site users, there is little research on the topic,
leaving an unclear picture of the actual state of cancer-relatedWeb
site users. Therefore, in this study, we conducted an access analysis
of cancer-related Web sites to shed light on the characteristics of
their visitors, which is information necessary for improving the
user friendliness of such Web sites.
Using Keyword Advice Tool (Overture KK, Tokyo, Japan),2
we first selected 96 keywords pertaining to cancer that have been
used in more than 3,000 searches per month on Yahoo! as of
September 2006. Next, we used the 96 selected keywords to con-
duct Yahoo! searches,3 and then selected 2,000Web sites that came
up in these searches. We then used Keyword Advice Tool to obtain
the number of searches performed with each keyword and ranked
the Web sites proportionate to the number of searches. Then we
computed a ranking score by giving the nth-ranking keyword of
the converted ranking a 1/n value (eg, the first-ranking site gets
1,000 points, the second-ranking site half of that, and so on). We
Table 1. Web Sites Analyzed
Classification Name of Web Site Aggregation Period
No. of Visitors
(daily average)
No. of Page Views
(daily average)
Cancer center Cancer center Web site A September 1, 2006 to November 30, 2006 — 42,663
Cancer center Cancer center Web site B October 1, 2006 to November 30, 2006 — 62,181
Hospital Hospital Web site C August 1, 2006 to November 30, 2006 8026 —
Hospital Cancer center Web site D March 26, 2006 to November 18, 2006;
October 15, 2006 to January 13, 2007
— —
Hospital Hospital Web site D October 1, 2006 to December 31, 2006 — 421
Hospital Hospital Web site E November 1, 2006 to December 31, 2006 — —
Pharmaceutical company Pharmaceutical company Web site A November 1, 2006 to December 31, 2006 — —
Pharmaceutical company Pharmaceutical company Web site B November 1, 2006 to December 31, 2006 — —
Pharmaceutical company Pharmaceutical company Web site C November 1, 2006 to December 31, 2006 — —
Pharmaceutical company Pharmaceutical company Web site D November 1, 2006 to December 31, 2006 — —
Pharmaceutical company Pharmaceutical company Web site E November 1, 2006 to December 31, 2006 — —
Individual Individual antiaging Web site A December 1, 2006 to December 31, 2006 — —
Cancer patient Cancer blog B October 1, 2006 to December 31, 2006 — —
Cancer patient Cancer blog C October 1, 2006 to December 31, 2006 — —
Cancer patient Cancer blog D December 2, 2006 to January 12, 2007 — —
Cancer patient Pediatric cancer blog E December 10, 2006 to January 27, 2007 — —
Cancer patient Pediatric cancer blog F December 10, 2006 to January 27, 2007 — —
Cancer patient Childhood leukemia blog G December 10, 2006 to January 27, 2007 — —
Cancer patient Leukemia blog H October 8, 2006 to January 8, 2007 — —
Cancer patient Leukemia blog I October 6, 2006 to January 5, 2007 — —
Cancer patient Breast cancer blog J January 1, 2007 to February 28, 2007 198 —
Cancer patient Breast cancer blog K January 1, 2007 to February 28, 2007 161 —
Cancer patient Leukemia blog L January 1, 2007 to February 28, 2007 173 —
Cancer patient Ureteral cancer blog M January 1, 2007 to February 28, 2007 51 —
Cancer patient Individual cancer link site N January 1, 2007 to February 28, 2007 — —
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